BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28846180)

  • 41. Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway.
    Lin MT; Lin CL; Lin TY; Cheng CW; Yang SF; Lin CL; Wu CC; Hsieh YH; Tsai JP
    Tumour Biol; 2016 May; 37(5):6987-96. PubMed ID: 26662956
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biological evaluation of a novel sorafenib analogue, t-CUPM.
    Wecksler AT; Hwang SH; Liu JY; Wettersten HI; Morisseau C; Wu J; Weiss RH; Hammock BD
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):161-71. PubMed ID: 25413440
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synergistic anti-tumor effects of the combination of a benzofuroxan derivate and sorafenib on NCI-H460 human large cell lung carcinoma cells.
    Teixeira SF; Alexandre de Azevedo R; Salomon MA; Jorge SD; Levy D; Bydlowski SP; Rodrigues CP; Pizzo CR; Barbuto JA; Ferreira AK
    Biomed Pharmacother; 2014 Oct; 68(8):1015-22. PubMed ID: 25312819
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synergistic activity of letrozole and sorafenib on breast cancer cells.
    Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG
    Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
    Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
    Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
    Zhao R; Li T; Zheng G; Jiang K; Fan L; Shao J
    Biomaterials; 2017 Oct; 143():1-16. PubMed ID: 28755539
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
    Kim MN; Ro SW; Kim DY; Kim da Y; Cho KJ; Park JH; Lim HY; Han KH
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):257-67. PubMed ID: 26037205
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
    BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.
    Gulhati P; Zaytseva YY; Valentino JD; Stevens PD; Kim JT; Sasazuki T; Shirasawa S; Lee EY; Weiss HL; Dong J; Gao T; Evers BM
    Carcinogenesis; 2012 Sep; 33(9):1782-90. PubMed ID: 22696593
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling.
    Wang H; Zhang C; Ning Z; Xu L; Zhu X; Meng Z
    Int J Oncol; 2016 Mar; 48(3):1229-41. PubMed ID: 26782953
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
    Gedaly R; Galuppo R; Musgrave Y; Angulo P; Hundley J; Shah M; Daily MF; Chen C; Cohen DA; Spear BT; Evers BM
    J Surg Res; 2013 Nov; 185(1):225-30. PubMed ID: 23769634
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activation of Focal Adhesion Kinase and Src Mediates Acquired Sorafenib Resistance in A549 Human Lung Adenocarcinoma Xenografts.
    Zhou Q; Guo X; Choksi R
    J Pharmacol Exp Ther; 2017 Dec; 363(3):428-443. PubMed ID: 29021381
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.
    Chen CH; Chen MC; Wang JC; Tsai AC; Chen CS; Liou JP; Pan SL; Teng CM
    Clin Cancer Res; 2014 Mar; 20(5):1274-1287. PubMed ID: 24520095
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway.
    Du W; Zhou JR; Wang DL; Gong K; Zhang QJ
    World J Surg Oncol; 2012 Apr; 10():60. PubMed ID: 22520038
    [TBL] [Abstract][Full Text] [Related]  

  • 55. VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.
    Kuiper JL; Lind JS; Groen HJ; Roder J; Grigorieva J; Roder H; Dingemans AM; Smit EF
    Br J Cancer; 2012 Nov; 107(11):1820-5. PubMed ID: 23079575
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.
    Wan J; Liu T; Mei L; Li J; Gong K; Yu C; Li W
    Br J Cancer; 2013 Jul; 109(2):342-50. PubMed ID: 23807172
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.
    Wang J; Ma S; Chen X; Zhang S; Wang Z; Mei Q
    Invest New Drugs; 2019 Oct; 37(5):828-836. PubMed ID: 30456603
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
    Pehserl AM; Ress AL; Stanzer S; Resel M; Karbiener M; Stadelmeyer E; Stiegelbauer V; Gerger A; Mayr C; Scheideler M; Hutterer GC; Bauernhofer T; Kiesslich T; Pichler M
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27916938
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.
    Wei G; Wang M; Carr BI
    J Cell Physiol; 2010 Jul; 224(1):112-9. PubMed ID: 20301194
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synergistic inhibition of characteristics of liver cancer stem-like cells with a combination of sorafenib and 8-bromo-7-methoxychrysin in SMMC-7721 cell line.
    Zou H; Cao X; Xiao Q; Sheng X; Ren K; Quan M; Song Z; Li D; Zheng Y; Zeng W; Cao J; Peng Y
    Oncol Rep; 2016 Sep; 36(3):1731-8. PubMed ID: 27461522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.